ImmunityBio reports 84 percent cystectomy avoidance. Six analysts rate ImmunityBio stock Buy

Published on 10/20/2026 at 20:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are scheduled for November 3, 2026. ImmunityBio stock costs EUR 7.87 on October 20, 2026, 18.87 percent below its 52-week high.

Clinical data and next date

ImmunityBio reported 84.00 percent cystectomy avoidance at three years on October 16, 2026.
Second-quarter revenue reached USD 51.24 million against a USD 49.70 million consensus estimate.
ImmunityBio stock costs EUR 7.87 at Lang & Schwarz on October 20, 2026 at 8:03 p.m. CEST, 18.87 percent below the 52-week high.

IBRX, US45256X1037, Illustration mit AI erstellt.

ImmunityBio (ISIN US45256X1037) reported on October 16, 2026 that 84.00 percent of patients in its ANKTIVA plus BCG study avoided cystectomy at three years. The company also said six analysts rated the stock Buy and one rated it Sell, according to MarketBeat. The stock was trading at EUR 7.87 at Lang & Schwarz on October 20, 2026 at 8:03 p.m. CEST.

Long-term response stays central

The clinical update concerned data from the QUILT-3.032 study in patients with BCG-unresponsive non-muscle-invasive bladder cancer. The company reported a 71.00 percent complete response rate and a median response duration of 26.60 months in the same October 16 release from ImmunityBio. Responses continued beyond 53 months in some patients, while the three-year cystectomy-free rate among responders was 84.00 percent.

What do the latest results show?

The latest reported quarter combined revenue growth with a continuing loss. MarketBeat reported second-quarter 2026 revenue of USD 51.24 million against a USD 49.70 million consensus estimate, while adjusted? No, the reported earnings per share loss was USD 0.22 versus a USD 0.08 expected loss. Revenue therefore exceeded the estimate by USD 1.54 million, but the earnings result missed by USD 0.14 per share.

Stock position and reporting date

The euro quote sits within a 52-week range of EUR 1.70 to EUR 9.70 reported for October 20, 2026. At EUR 7.87, ImmunityBio stock stood 18.87 percent below that high and 362.94 percent above the low. The market capitalization was USD 9.4 billion as of October 20, 2026, while the primary listing is on Nasdaq under ticker IBRX.

The next scheduled reporting date is November 3, 2026, when ImmunityBio is estimated to report third-quarter results before the US market opens, according to MarketBeat. The company also lists ESMO from October 23 through October 27 among its upcoming industry events.

Price remains below the yearly high

ImmunityBio's euro quotation remains below its 52-week high even as the latest clinical data provide a dated operating reference. The stock's market value and the second-quarter revenue figure place the clinical progress alongside a business that is still reporting losses.

ImmunityBio stock was trading at EUR 7.87 at Lang & Schwarz on October 20, 2026 at 8:03 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of ImmunityBio stock.